| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Hypertension. 1995;26:279-284.)
© 1995 American Heart Association, Inc.
Articles |
Altered Angiotensinogen Amino Acid Sequence and Plasma Angiotensin II Levels in Genetically Hypertensive Rats
A Study on Cause and Effect
From the Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, and the Department of Cardiology, Children's Hospital, Harvard Medical School, Boston, Mass (N.H., R.K., K.L.); the Department of Applied Biology, Kyoto (Japan) Institute of Technology (S.T.); and the Max Delbrück Center for Molecular Medicine, Berlin, Germany (D.G.).
Correspondence to Klaus Lindpaintner, MD, Cardiovascular Division, Brigham and Women's Hospital, 75 Francis St, Boston, MA 02115.
Abstract The components of the renin-angiotensin system have been implicated in the development of primary hypertension in humans and genetically hypertensive rats. In humans a mutation in the angiotensinogen gene and elevated plasma angiotensinogen levels have been linked to primary hypertension. Although we had previously excluded a linkage of blood pressure to the angiotensinogen gene in the stroke-prone spontaneously hypertensive rat (SHRSP), elevated angiotensin II (Ang II) levels in this strain compared with the normotensive reference, the Wistar-Kyoto rat (WKY), prompted us to investigate further into the origins and effects of altered Ang II regulation using a range of physiological, biochemical, molecular, and genetic approaches. Ang II plasma levels determined by radioimmunoassay were confirmed to be significantly elevated in SHRSP compared with WKY. Sequence comparison among the two rat strains revealed a mutation in the coding region of the angiotensinogen gene that results in an isoleucine-to-valine substitution in SHRSP at amino acid position 154 (I154V). We performed a cosegregation analysis in an F2 intercross cohort bred from SHRSP and WKY from the University of Heidelberg (SHRSPHD and WKYHD) to address the following questions: (1) whether this or another mutation of the angiotensinogen gene may be causally related to the observed differential Ang II plasma levels, (2) whether Ang II plasma levels may be correlated with blood pressure or organ hypertrophy, and (3) whether genetic linkage to the renin or angiotensin-converting enzyme (ACE) gene loci (the two classic regulatory enzymes of the renin-angiotensin system) may provide an explanation for elevated Ang II plasma levels. We measured Ang II plasma concentrations and determined systolic and diastolic pressures as well as heart rate by indwelling arterial catheters in conscious rats before and after dietary sodium loading. We found (1) no linkage of the angiotensinogen gene mutation to Ang II plasma levels, (2) no cosegregation of Ang II plasma levels with blood pressure or morphometric parameters, and (3) no linkage of Ang II plasma levels to either the renin gene or the ACE gene locus, excluding a genetically determined regulatory effect on Ang II plasma levels of either enzyme. Of all other parameters measured in this cross, only plasma renin activity showed a significant correlation with Ang II plasma levels. Thus, the demonstrated angiotensinogen mutation has no effect on plasma Ang II levels; Ang II plasma levels do not account for, do not contribute to, and are not caused by elevated blood pressure in SHRSPHD; and altered Ang II plasma levels in SHRSPHD are not genetically determined by the renin or ACE gene. We conclude that elevated Ang II levels in SHRSPHD are likely to represent an independent, unrelated phenomenon that is of no direct relevance to the pathogenesis of hypertension.
Key Words: angiotensin II • hypertension, primary • genetics • linkage (genetics) • renin-angiotensin system
This article has been cited by other articles:
 |
|
 |
|
  M. A. F. De Godoy and S. Rattan Angiotensin-Converting Enzyme and Angiotensin II Receptor Subtype 1 Inhibitors Restitute Hypertensive Internal Anal Sphincter in the Spontaneously Hypertensive Rats J. Pharmacol. Exp. Ther., August 1, 2006; 318(2): 725 - 734. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Raasch, C. Wittmershaus, A. Dendorfer, I. Voges, F. Pahlke, C. Dodt, P. Dominiak, and O. Johren Angiotensin II Inhibition Reduces Stress Sensitivity of Hypothalamo-Pituitary-Adrenal Axis in Spontaneously Hypertensive Rats Endocrinology, July 1, 2006; 147(7): 3539 - 3546. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Zicha and J. Kunes Ontogenetic Aspects of Hypertension Development: Analysis in the Rat Physiol Rev, October 1, 1999; 79(4): 1227 - 1282. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. P. Healy and L. Song Kidney Aminopeptidase A and Hypertension, Part I : Spontaneously Hypertensive Rats Hypertension, February 1, 1999; 33(2): 740 - 745. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. E. McEwan, G. A. Gray, L. Sherry, D. J. Webb, and C. J. Kenyon Differential Effects of Angiotensin II on Cardiac Cell Proliferation and Intramyocardial Perivascular Fibrosis In Vivo Circulation, December 15, 1998; 98(24): 2765 - 2773. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Corvol and X. Jeunemaitre Molecular Genetics of Human Hypertension: Role of Angiotensinogen Endocr. Rev., October 1, 1997; 18(5): 662 - 677. [Abstract] [Full Text]
|
|
|
|
 |
|
 A. B. MacLeod, S. Vasdev, and J. S. Smeda The Role of Blood Pressure and Aldosterone in the Production of Hemorrhagic Stroke in Captopril-Treated Hypertensive Rats Stroke, September 1, 1997; 28(9): 1821 - 1829. [Abstract] [Full Text]
|
|
|
|
|
|
N. Sato, T. Katsuya, H. Rakugi, S. Takami, Y. Nakata, T. Miki, J. Higaki, and T. Ogihara Association of Variants in Critical Core Promoter Element of Angiotensinogen Gene With Increased Risk of Essential Hypertension in Japanese Hypertension, September 1, 1997; 30(3): 321 - 325. [Abstract] [Full Text]
|
|